J Pharm Pharmacogn Res 2(Suppl. 1): S24, 2014
Special supplement with the abstract book of LATINFARMA 2013
CO 045: NSAID AND GASTROPROTECTIVE AGENTS PRESCRIPTION AT THE CLINICAL HOSPITAL “DR. MANUEL QUINTELA”
Cuñetti L, Catenaccio V, Ramos C, Viroga S, Artagaveytia P, Speranza N, Tamosiunas G.Departamento de Farmacología y Terapéutica – Facultad de Medicina, Universidad de la República, Hospital de Clínicas Av. Italia s/n Montevideo, Uruguay. E-mail: firstname.lastname@example.org
Introduction: NSAID are one of the most used drugs worldwide. In order to reach a rational use of this group of drugs we need to know it´s use in our hospital in which we also have a List of Essential Medicines.
Objective: Our aim is to determine NSAID prescription profile and the use of gastro-protection strategies in our hospital.
Methods: Descriptive transversal study, analyzing clinical records of all patients hospitalized during August 3rd, 2012 in the Clinical Hospital. Data collection was performed by medical students and staff of our department. A preformed form was filled out, and a pilot study took place to unify criteria. NSAID prescription and of any medicine associated to a different gastrointestinal risk were evaluated. We classified either the patients or the NSAID in low or high risk to develop NSAID gastroenteropathy.
Results: 239 clinical records were evaluated, 156 (65%) had at least one NSAID prescribed. 50% of NSAID were administered intravenously. 20.5% were for antiplatelet therapy, 80% were indicated for pain or/and fever. From all the patients who received NSAID 108 (69.2%) had at least one risk factor to develop NSAID gastroenteropathy. 59 (55%) had omeprazol 19 (17%) had ranitidine and 30 (27.7%) didn’t have any gastroprotective treatment. From this 30, 6 had one risk factor associated to a low risk NSAID; the rest (24 cases) had various risk factors and/or at least one high risk NSAID. From the 48 patient without risk to develop NSAID gastroenteropathy, 22 (14.2%) almost half of them had gastroprotection associated.
Conclusions: We need to study the use of intravenous route of NSAID and to improve the selection of risk patients and the association of gastroprotective agents in the NSAID prescription. We still have more to do in order to use this group of medicines in a rational manner.